Cargando…
Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease characterized by the persistence of activated myofibroblasts resulting in excessive deposition of extracellular matrix proteins and profound tissue remodeling. Myofibroblasts have been shown to arise from inters...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899580/ https://www.ncbi.nlm.nih.gov/pubmed/24478703 http://dx.doi.org/10.3389/fphar.2014.00002 |
_version_ | 1782300595958317056 |
---|---|
author | Habiel, David M. Hogaboam, Cory |
author_facet | Habiel, David M. Hogaboam, Cory |
author_sort | Habiel, David M. |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease characterized by the persistence of activated myofibroblasts resulting in excessive deposition of extracellular matrix proteins and profound tissue remodeling. Myofibroblasts have been shown to arise from interstitial fibroblasts, epithelial to mesenchymal transition of type II alveolar epithelial cells, and the differentiation of recruited fibrocytes. There are many mechanisms that are utilized by these cells for survival, proliferation, and persistent activation including up-regulation of cytokines [i.e., Interleukin 6 (IL-6) and C-C motif chemokine ligand 21 (CCL21)], cytokine receptors [i.e., Interleukin 6 Receptor 1 (IL-6R1), Glycoprotein 130 (gp130) and C-C Chemokine Receptor type 7 (CCR7)], and innate pattern recognition receptors [(PRRs; i.e., Toll Like Receptor 9 (TLR9)]. In this review, we will discuss the role of the cytokines IL-6 and CCL21, their receptors and the PRR, TLR9, in fibroblast recruitment, activation, survival, and differentiation into myofibroblasts in IPF. |
format | Online Article Text |
id | pubmed-3899580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-38995802014-01-29 Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis Habiel, David M. Hogaboam, Cory Front Pharmacol Pharmacology Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease characterized by the persistence of activated myofibroblasts resulting in excessive deposition of extracellular matrix proteins and profound tissue remodeling. Myofibroblasts have been shown to arise from interstitial fibroblasts, epithelial to mesenchymal transition of type II alveolar epithelial cells, and the differentiation of recruited fibrocytes. There are many mechanisms that are utilized by these cells for survival, proliferation, and persistent activation including up-regulation of cytokines [i.e., Interleukin 6 (IL-6) and C-C motif chemokine ligand 21 (CCL21)], cytokine receptors [i.e., Interleukin 6 Receptor 1 (IL-6R1), Glycoprotein 130 (gp130) and C-C Chemokine Receptor type 7 (CCR7)], and innate pattern recognition receptors [(PRRs; i.e., Toll Like Receptor 9 (TLR9)]. In this review, we will discuss the role of the cytokines IL-6 and CCL21, their receptors and the PRR, TLR9, in fibroblast recruitment, activation, survival, and differentiation into myofibroblasts in IPF. Frontiers Media S.A. 2014-01-23 /pmc/articles/PMC3899580/ /pubmed/24478703 http://dx.doi.org/10.3389/fphar.2014.00002 Text en Copyright © 2014 Habiel and Hogaboam. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Habiel, David M. Hogaboam, Cory Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis |
title | Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis |
title_full | Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis |
title_fullStr | Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis |
title_full_unstemmed | Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis |
title_short | Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis |
title_sort | heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899580/ https://www.ncbi.nlm.nih.gov/pubmed/24478703 http://dx.doi.org/10.3389/fphar.2014.00002 |
work_keys_str_mv | AT habieldavidm heterogeneityinfibroblastproliferationandsurvivalinidiopathicpulmonaryfibrosis AT hogaboamcory heterogeneityinfibroblastproliferationandsurvivalinidiopathicpulmonaryfibrosis |